A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2)

study id #: NCT03406780

condition: Muscular Dystrophies, Muscular Dystrophy, Duchenne, Muscular Disorders, Atrophic, Muscular Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn

status: active, not recruiting

HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne muscular dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.

intervention: CAP-1002, Placebo

mechanism of action: Cardiac progenitor cells to promote cellular regeneration

results: https://clinicaltrials.gov/ct2/show/results/NCT03406780

last updated: February 15, 2019

start date: April 4, 2018

estimated completion: December 2019

phase of development: Phase 2

size / enrollment: 18

study description:
• Approximately 84 eligible study participants will be randomized to either CAP-1002 or placebo in a 1:1 ratio.
• The trial will include visits at Screening, Baseline/Day 1, Week 4, and Months 3, 6, 9, and 12 with IV infusions of CAP-1002 or placebo on Day 1 and Months 3, 6, and 9.
• Safety evaluations will include adverse events, concomitant medications, physical exam, vital signs, 12-lead ECG, and clinical laboratory testing.
• Efficacy will be evaluated in the Performance of the Upper Limb, pulmonary function testing, North Star Ambulatory Assessment (ambulatory subjects only), strength testing, cardiac MRI, and quality of life.
• If trial data suggests an appropriate risk/benefit profile of CAP-1002, Capricor, upon the recommendation of the Data Safety Monitoring Board (DSMB), will introduce an open-label extension study to offer CAP-1002 to study participants who were randomized to placebo and completed all trial visits during the 12-month period.

primary outcomes:

• Change in the mid-level (elbow) dimension of the Performance of the Upper Limb (PUL) [ Time Frame: Month 12 ]
  The PUL includes functional tasks that relate to activities of daily living that are very important for quality of life. The PUL has been validated for the assessment of upper limb motor function in individuals with DMD.

secondary outcomes:

• Change in the mid-level (elbow) dimension of the PUL [ Time Frame: Months 3, 6, and 9 ]
  The PUL includes functional tasks that relate to activities of daily living that are very important for quality of life. The PUL has been validated for the assessment of upper limb motor function in individuals with DMD.
• Change in regional systolic left ventricular wall thickening as assessed by cardiac MRI [ Time Frame: Months 6 and 12 ]
  Systolic thickening is thought to be a principal mechanism of cardiac output generation in people with DMD.

inclusion criteria:
• Genetically confirmed DMD
• Reduced upper arm strength as measured by the Performance of Upper Limb
• Reduced ability to walk/run (if ambulatory)
• Treatment with systemic glucocorticoids for at least 12 months and at a stable dose at least 6 months prior to study participation, except for weight-based or toxicity-related adjustments
• Current and up-to-date immunizations

exclusion criteria:
• Left ventricular ejection fraction < 35%
• BMI > 45
• Ambulant if >= 18 years of age
• Exon 44 skip-amenable mutation(s) in the DMD gene
• Deletion mutation(s) encompassing exons 3-7 of the DMD gene
• Percent-predicted forced vital capacity (FVC) < 35%
• Chronic respiratory disease not related to DMD (for example, asthma, bronchitis, and tuberculosis)
• History of diabetes requiring treatment with metformin or insulin within 3 months prior to randomization
• Treatment with an FDA-approved exon skipping therapy for the treatment of DMD if on a stable dose for less than 24 months prior to randomization
• Treatment with human growth hormone (HGH) within 3 months prior to randomization, unless on a stable dose for at least 24 months prior to randomization
• Treatment with idebenone within 3 months prior to randomization
• Treatment with a cell therapy product within 12 months prior to randomization
• Treatment with an investigational product within 6 months prior to randomization

sponsor: Capricor Inc.

investigators: Craig McDonald, MD; Catherine Kelleher, MD

locations: United States